Measurable residual disease testing for personalized treatment of acute myeloid leukemia
Mats Ehinger1, Louise Pettersson2,3
1Department of Clinical Sciences, Pathology, Skane University Hospital, Lund University, Lund, Sweden.
Abstract:
This review summarizes - with the practicing hematologist in mind - the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.
More Related Videos
Related Concept Videos
Self-Report Tests of Personality
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Residual Stresses
Residual Plots
When the residual values are plotted against the variable x, it is called a residual...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids


